Clinical Trial Update: Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome [NA]

View source ↗

Summary

Completed clinical trial evaluating low-flow extracorporeal carbon dioxide removal for COVID-19-associated acute respiratory distress syndrome. The study also i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercapnic Respiratory Failure
• Kidney Injury
• Respiratory Distress Syndrome

Snippet

Sponsor: University of Giessen | Conditions: ARDS, Hypercapnic Respiratory Failure | NA | Status: COMPLETED